Cachexia—a syndrome characterized by progressive muscle wasting—affects both humans and dogs with chronic diseases such as cancer. A recent study in ...

Cachexia-a syndrome characterized by progressive muscle wasting-affects both humans and dogs with chronic diseases such as cancer.

Cachexia—a syndrome characterized by progressive muscle wasting—affects both humans and dogs with chronic diseases such as ...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that ...

NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors - - In head-to-head in vivo studies, ...

A new therapeutic target for treating sarcopenia, the age-related loss of muscle mass, and cachexia, the severe muscle ...

Scientists are getting closer to understanding the wasting and fatigue that often accompanies cancer. Treatments could be on ...

Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew ...

A new study suggests that poor muscle health may affect blood sugar regulation, increasing the risk of type 2 diabetes and ...

North Americans find few things sexier than the promise of a quick fitness fix, from the vibration belts of the 1930s, to the ...

Lkb1-mutant lung tumors release prostaglandin E2, triggering signaling via lung sensory neurons and the vagus nerve to reduce ...

Findings suggest broader utility in cancer supportive care, building on interim findings from CAReS Phase 2 clinical study which demonstrated improvements in body weight, lean body mass and activity ...